Akamis Bio
PrivateLast Round
Series A
Dec 17, 2024
Total Funding Raised
$226.8M
Company Overview
Akamis Bio is a biotechnology company developing systemically administered oncolytic immunotherapies to treat solid tumors through its proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Akamis Bio Comparables
Compare Akamis Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Virogin Biotech | 85% | |
| Theolytics | 83% | |
| Lokon Pharma | 81% | |
Akamis Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 17, 2024 | ||||
| Convertible Debt | Jan 5, 2023 | ||||
| Corporate Funding | Dec 20, 2016 | ||||
| Series C | May 19, 2015 | ||||
| Grant | Nov 6, 2012 | ||||
Series B | Jul 19, 2012 |
Key People
Founding team and executive leadership
Akamis Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lundbeck Foundation | Series B, Series C |
| Invesco Ltd. | Series B, Series A, VC Round, Series C |
| Westlake Village BioPartners | Convertible Debt |
| IP Group | Convertible Debt |
| Lundbeckfonden BioCapital | Series B, Series C |
| ARCH Venture Partners | Convertible Debt |
| Parker Institute for Cancer Immunotherapy | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 14, 2025
NG-350A receives designation for advanced rectal cancer treatment.
- Aug 12, 2025
Andrew Hirsch appointed to the Board of Directors.
Akamis Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Akamis Bio's valuation, stock price, and market status.